Artificial intelligence (AI) software developer Lunit has received commercial approval in Taiwan for its software product for mammography analysis.
Lunit Insight MMG is one of the company's most mature radiology products. The AI software analyzes mammography images to detect suspicious lesions in mammography images, helping radiologists distinguish suspected tumor areas by providing the location of the lesion with an abnormality score reflecting the AI's confidence level, Lunit said.
Lunit Insight MMG was cleared by the U.S. Food and Drug Administration last year and by Health Canada in June.
